Daniel Hutchins

Cooley advised underwriters on IGM Biosciences’ $201.3 million initial public offering of 12,578,125 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Piper Jaffray, Stifel, Nicolaus & Company and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences’ securities now trade on the Nasdaq Global Select Market under the symbol “IGMS.” Partners Jonie Kondracki, Charlie Kim, Dave Peinsipp and Will Cai led the Cooley team.

Cooley advised Atreca on its $125 million initial public offering of 7,350,000 shares of common stock. Atreca, whose securities now trade on the Nasdaq Global Select Market under the symbol “BCEL,” is a biopharmaceutical company using a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Partners Barbara Kosacz, Danielle Naftulin and Mike Tenta led the Cooley team.

Cooley advised the underwriters on AbCellera Biologic’s $556 million initial public offering of 27,772,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC and BMO Capital Markets Corp. acted as the joint book-running managers for the offering. AbCellera Biologics, whose securities now trade on the Nasdaq Global Market under the symbol “ABCL,” is a technology company that aims to become the centralized operating system for next-generation antibody discovery. Partners Charlie Kim, Kristin VanderPas, Div Gupta and Rich Segal led the Cooley team.